Related by context. All words. (Click for frequent words.) 70 CCX# 69 HGS ETR1 69 BiTE 69 Tarvacin TM 68 ENMD # 68 HCD# [002] 68 ganetespib 68 immunotherapeutic 68 MT# MEDI 68 PDE4 inhibitor 68 MEK inhibitor 68 targeting CD# 67 Aurora kinase 67 PLK1 SNALP 67 HCV protease inhibitor 67 humanized anti 67 mitogen activated ERK kinase 67 AP# [003] 67 JAK1 67 Nanobody 67 Solazed 67 targeted radiotherapeutic 66 OncoVEX 66 ALN TTR# 66 PNP inhibitor 66 alvespimycin 66 IMA# 66 Sym# 66 OncoVEX GM CSF 66 BiTE ® 66 Azedra 66 radiation sensitizer 66 multi kinase inhibitor 66 trastuzumab DM1 T DM1 66 investigational humanized monoclonal antibody 66 ASONEP 66 ALN PCS 66 JAK2 inhibitor 66 EndoTAG TM 66 OXi# 66 ALN VSP 66 HGS ETR2 65 histone deacetylase HDAC inhibitor 65 orally bioavailable 65 therapeutic monoclonal antibody 65 Aurexis 65 Guanilib 65 Hedgehog antagonist 65 oral prodrug 65 IRX 2 65 blinatumomab 65 CEQ# 65 VitiGam 65 hematological cancers 65 RNAi therapeutic 65 RhuDex ® 65 Zemiva TM 65 mertansine 65 ALN TTR 65 immunotherapeutics 65 MT#/MEDI-# 65 DOS# 65 NEUMUNE 65 Tarmogen 65 obatoclax 64 OMP #M# 64 TKM ApoB 64 RGB # 64 XmAb 64 Solazed TM 64 Nanobody ® 64 depsipeptide 64 EndoTAG TM -1 64 Trofex 64 liposomal formulation 64 personalized immunotherapy 64 ApoB SNALP 64 PEG SN# 64 protein kinase inhibitor 64 MAXY G# 64 DXL# 64 CYC# 64 Phase Ib study 64 HQK 64 proteasome inhibitor 64 adecatumumab 64 siRNA therapeutics 64 novel anticancer 64 GRNVAC1 64 systemic RNAi therapeutic 64 OvaRex R 64 oncolytic 64 Factor VIIa 64 BiTE antibodies 64 Aurora kinase inhibitor 63 huC# DM4 63 MGCD# [001] 63 Onalta 63 humanized monoclonal antibody 63 Blinatumomab 63 otelixizumab 63 IAP inhibitor 63 TG# [003] 63 PSMA ADC 63 BAY #-# 63 NXL# 63 dacetuzumab 63 Nanobodies 63 GRN# 63 JAK inhibitor 63 adecatumumab MT# 63 Shigamabs ® 63 PI3K/Akt pathway inhibitor 63 PRT# 63 Amigal 63 MAGE A3 ASCI 63 BiTE R 63 Iluvien ® 63 HuLuc# 63 HuMax CD4 63 Proxinium TM 63 humanized monoclonal antibodies 63 selective kinase inhibitor 63 HSP# inhibitor 63 Ceflatonin 63 AEG# 63 XL# XL# 63 Genasense ® 63 Virulizin ® 63 pralatrexate 63 NovaBay Aganocide compounds 63 Alocrest 63 Hedgehog pathway inhibitor 63 IAP inhibitors 63 bafetinib 63 TREANDA 63 PORxin TM 63 Alzhemed TM 63 Aplidin R 63 ATL# [001] 63 Aplidin 63 vascular disrupting agent 63 Sphingomab 63 BHT DNA 62 pradefovir 62 ELACYT 62 PrevOnco 62 talactoferrin 62 anticancer therapeutics 62 stable nucleic acid 62 leading oral taxane 62 preclinically 62 nicotinic alpha 7 62 CR# vcMMAE 62 EndoTAG 62 CD# monoclonal antibody 62 DPX Survivac 62 humanized antibodies 62 AQ4N 62 therapeutic antibody 62 volociximab 62 rxRNA 62 MLN# 62 XmAb# 62 histone deacetylase inhibitor 62 cancer immunotherapies 62 epothilone 62 histone deacetylase HDAC 62 SNALP technology 62 PSN# [002] 62 selective androgen receptor modulator 62 novel peptide 62 ATL# [002] 62 JAK inhibitors 62 SAR# [004] 62 receptor tyrosine kinase inhibitor 62 drug conjugate 62 romidepsin novel 62 DsiRNA 62 INCB# [001] 62 Perifosine 62 Alpharadin 62 EP #R 62 investigational monoclonal antibody 62 siRNA therapeutic 62 drug conjugate ADC 62 generation antisense 62 MyVax R 62 Atiprimod 62 candidate REP# 62 virus HCV protease inhibitor 62 EOquin 62 PRX# 62 CD# antibody [001] 62 PXD# 62 Neuradiab 62 vidofludimus 62 Azedra ™ 62 metaglidasen 62 Allovectin 7 62 chemically modified siRNA 62 YONDELIS 62 ridaforolimus 62 phase IIb clinical 62 AVN# [001] 62 antisense drug 62 Anticalin R 62 UVIDEM 62 XL# XL# XL# XL# 62 Personalized Immunotherapy 62 IMC #B 62 DCVax ® 62 therapeutic monoclonal antibodies 61 novel histone deacetylase 61 Chemophase 61 RDEA# 61 Bezielle 61 registrational 61 Voreloxin 61 R#/MEM # 61 Acute Radiation Syndrome ARS 61 Phase 2a trial 61 DCVax R 61 Panzem R NCD 61 TKM PLK1 61 preclinical 61 adenovector 61 immunomodulatory 61 Scancell 61 polysaccharide polymer 61 eniluracil 61 MOZOBIL 61 TLR9 agonist 61 Tarvacin 61 MGd 61 Thiarabine 61 GSK '# 61 #D#C# 61 PDX pralatrexate 61 investigational pan BCR 61 Traficet EN 61 Angiocept 61 hematological malignancies 61 investigational therapies 61 TOCOSOL Camptothecin 61 candidate deforolimus 61 perifosine 61 castration resistant prostate cancer 61 GLP toxicology studies 61 NPC 1C 61 GVAX ® 61 PS# [001] 61 anticancer agent 61 TRO# 61 MVA BN R 61 orally administered inhibitor 61 teplizumab 61 myelofibrosis polycythemia vera 61 Aganocide ® 61 HGS# 61 LEAPS TM 61 TLR8 61 Carfilzomib 61 Phase #b/#a clinical 61 TLR9 agonists 61 anti CD3 monoclonal 61 EpCAM 61 Onconase 61 humanized antibody 61 TOCOSOL Paclitaxel 61 HuCAL antibody 61 orally dosed 61 IL# PE#QQR 61 HspE7 61 DermaVir Patch 61 torezolid phosphate 61 CD# CEA 61 phase IIa clinical 61 AzaSite Xtra 61 A3 adenosine receptor 61 immune stimulatory 61 Phase #/#a trial 61 candidate CRLX# 61 anticancer compound 61 Amplimexon 61 MAP# 61 Anticalin 61 TPI ASM8 61 GSK # 61 Tesetaxel 61 GAP #B# 61 Zemiva ™ 61 immunomodulator 61 GRN#L 61 HCV protease 61 targeted antifolate 61 Anticalin ® 61 EOquin TM 61 lintuzumab 61 PEGylated 61 Azixa 61 HuMax EGFr 61 Homspera 61 MEK inhibitors 61 elacytarabine 61 immunotherapeutic vaccine 61 gallium containing 61 BCR ABL inhibitors 61 Sudhir Agrawal D.Phil 61 NEUGENE 61 immunotherapeutic agent 61 TRAIL receptor 61 BrachySil TM 61 atacicept 61 non nucleoside inhibitor 61 Vicinium TM 61 valopicitabine 61 MyVax ® 61 Hemopurifier ® 61 Panzem R 61 isoform selective 61 Protexia ® 61 Aganocide R 61 Onalta ™ 61 UltiMAb 61 forodesine 61 Allovectin 7 R 60 Veronate 60 Protexia R 60 FGFR 60 molecular imaging radiopharmaceuticals 60 LEX System 60 anti CD# antibodies 60 bevacizumab Avastin ® 60 XmAb ® 60 tivozanib 60 Phase IIb clinical trials 60 MEK inhibitor RDEA# 60 OvaRex ® MAb 60 SAR# [002] 60 Azedra TM 60 ongoing Phase 1b 60 TELCYTA TM TLK# 60 Clavis Pharma 60 MAb 60 enzastaurin 60 Panzem 60 Hybridon 60 non nucleoside HCV 60 selective orally bioavailable 60 tanespimycin 60 Alnylam #x# 60 oral antiviral 60 elotuzumab 60 AzaSite Plus 60 LE DT 60 IMP# 60 Oral NKTR 60 deforolimus 60 Tamibarotene 60 Bicifadine 60 RAV# 60 registrational trial 60 Bendavia 60 selective inhibition 60 alpha folate receptor 60 LentiVector technology 60 novel immunomodulatory 60 entinostat 60 rPA anthrax vaccine 60 Marqibo TM 60 ATL/TV# 60 replicon 60 Diamyd ® 60 Xcellerated T Cells 60 Phase 2b trial 60 MDV# 60 XL# [003] 60 Synavive 60 XmAb ™ 60 Phase Ib clinical trials 60 Virulizin R 60 Allovectin 7 ® 60 investigational compound 60 Exelixis compounds 60 pharmacological chaperone 60 perifosine KRX 60 JZP 60 Nexavar sorafenib 60 vascular disrupting agents 60 THR beta agonist 60 CYT# potent vascular disrupting 60 HGS ETR1 mapatumumab 60 anti CD# antibody 60 ALN HTT 60 FluCide 60 INCB# [002] 60 Symadex 60 ENMD 60 Vaxfectin 60 brentuximab vedotin SGN 60 LHRH antagonist 60 JAK3 60 PCK# 60 PLX# 60 Fleximer 60 Neo Kidney Augment 60 Prednisporin 60 Hsp# inhibitor 60 glucokinase activator 60 Micromet BiTE 60 TLR7 60 CBLC# 60 LymphoStat B TM 60 Archexin 60 molecularly targeted 60 L BLP# 60 CA4P 60 adenoviral 60 antibody MT# 60 Alfacell proprietary ribonuclease 60 anticancer activity 60 imetelstat 60 small molecule defensin 60 therapeutic peptide 60 cMET 60 Harbor BioSciences 60 XP# XP# 60 tumor antigen 60 Restanza 60 Triolex 60 Tyrima 60 GMX# 60 monoclonal antibody 60 TACI Ig 60 Azedra TM Onalta TM 60 G#DT 60 SynCon TM DNA 60 monoclonal antibody mAb 60 HIV integrase inhibitors 60 RNAi therapeutic targeting 60 Valortim 60 PLX cells 60 sodium glucose cotransporter 60 tosedostat 60 BiovaxID TM 60 rBChE 60 POTELLIGENT ® 60 REP# 60 XL# anticancer compounds 60 VEGF receptor inhibitor 60 defensin mimetic antibiotic 60 antitumor 60 DAVANAT 60 Locteron ® 60 chemotherapy induced neutropenia 60 peptide antigens 60 oxidative stress inducer 60 Urocidin TM 60 CD3 monoclonal antibody 60 GPR# agonist 60 TRAIL Receptor 60 Medarex UltiMAb R 60 Multimeric 60 BEMA TM Fentanyl 60 synthetic retinoid 60 Phase Ib 60 XmAb TM 60 romidepsin 60 Cloretazine ® 60 Onalta TM 60 preclinical studies 60 maturation inhibitor 60 Cloretazine R 60 Debio 60 Solazed ™ 60 TG# [001] 60 epothilones 59 pertuzumab 59 ruxolitinib 59 angiogenesis inhibitor 59 oncolytic virus 59 Aflibercept 59 polymerase inhibitor 59 non nucleoside 59 Romidepsin 59 Exherin TM 59 chemokine receptor 59 tubulin inhibitor 59 Dapagliflozin 59 GED aPC 59 bortezomib Velcade ® 59 BiovaxID 59 prophylactic vaccine 59 axitinib 59 HepaGam B 59 APOPTONE 59 systemically administered 59 effector function 59 PEG Interferon lambda 59 JVRS 59 JNJ Q2 59 SinuNase ™ 59 mapatumumab 59 Combidex 59 tesetaxel 59 CUDC 59 selective immunoproteasome inhibitor 59 Troxatyl 59 XOMA 3AB 59 cleavable linker 59 Hematide TM 59 Annamycin 59 Hsp# inhibition 59 MYDICAR ® 59 VEGFR2 inhibitor 59 CORT # 59 kinase inhibitor 59 Telatinib 59 hormone LHRH antagonist 59 Onco TCS 59 IgG1 monoclonal antibody 59 immune modulatory 59 Hedgehog inhibitor 59 VQD 59 investigational drug 59 M Vax 59 sodium thiosulfate STS 59 Radezolid 59 PROSTVAC TM 59 somatostatin analogue 59 Radilex 59 Transdrug ® nanoparticle 59 Vaxfectin TM 59 Amrubicin 59 small molecule thrombopoietin 59 Allovectin 7 r 59 LNPs 59 anti CD3 antibody 59 recombinant polyclonal antibody 59 dasatinib Sprycel ® 59 targets Galectin receptors 59 Quinamed 59 molecular imaging radiopharmaceutical 59 Preclinical studies suggest 59 MGCD# [002] 59 pan HDAC inhibitor 59 PI3K inhibitor 59 NTDDS 59 Shigamabs R 59 ABL inhibitor 59 radiotherapeutic 59 fipamezole 59 OMP #R# 59 ALN RSV# 59 NEUGENE antisense 59 preclinical efficacy 59 Lixivaptan 59 PI3K inhibitors 59 HepeX B 59 Pradefovir 59 Akt inhibitor 59 ChemoCentryx 59 immunotherapies 59 Kahalalide F 59 Trofex TM 59 Talabostat 59 monoclonal 59 CGEN # 59 candidate TNFerade biologic 59 motexafin gadolinium Injection 59 docetaxel Taxotere ® 59 PRTX 59 radiolabeled monoclonal antibody 59 TKM Ebola 59 polymerase inhibitors 59 Civacir 59 indibulin 59 Spiegelmer ® 59 Tolerx 59 PrevOnco ™ 59 JAK2 inhibitors 59 ZFP Therapeutic 59 Litx 59 relapsed multiple myeloma 59 Vaxfectin R adjuvant 59 bispecific antibody 59 small molecule glucokinase 59 anti amnesic 59 milatuzumab 59 NeuroVax TM 59 IL# PE 59 SparVax ™ 59 HDL Mimetic Peptide 59 SynCon ™ DNA 59 IMiD 59 EGS# 59 POTELLIGENT R Technology 59 Crucell PER.C6 ® 59 allosteric modulator 59 HTS assay 59 small molecule inhibitors 59 hematological tumors 59 polyclonal antibody 59 neuroprotective properties 59 MAXY alpha 59 sodium glucose transporter 59 SinuNase 59 immunological diseases 59 IMC A# 59 Vaccinex 59 KNS # 59 thymalfasin 59 Panzem NCD 59 TELINTRA 59 RiVax 59 Phase 2a clinical trials 59 prophylactic vaccines 59 recombinant antibodies 59 Phase 1b clinical trials 59 Maxy G# 59 ALK inhibitor 59 irreversible inhibitor 59 Curaxin 59 VLP vaccine 59 FLT3 59 NP2 Enkephalin 59 antibody MAb 59 lintuzumab SGN 59 Seliciclib 59 selective inhibitor 59 exon skipping 59 Gleevec resistant 59 Pancreate 59 Vitaxin 59 Altastaph 59 HuCNS SC ® 59 telomerase therapeutic 59 humanized monoclonal 59 BAL# [001] 59 Pathway Inhibitor 59 TAFA# 59 TELCYTA 59 vemurafenib 59 amrubicin 59 ospemifene 59 PKC# 59 Kosan dependence 59 ProLindac 59 immunostimulatory 59 Protectan CBLB# 59 BRAF inhibitor 59 IND submission 59 systemic RNAi 59 preclinical compounds 59 Anthim 59 HEPLISAV ™ 59 talabostat 59 antisense inhibitors 59 Surfaxin LS 59 evaluating tivozanib 59 including eniluracil ADH 59 ZK EPO 58 accumulate preferentially 58 small molecule inhibitor 58 Apoptone 58 EZN 58 CCR5 mAb 58 L DOS# 58 imatinib Gleevec ® 58 nanoviricide 58 CCR9 antagonist 58 M2 subunit 58 investigational antibody 58 Stimuvax R 58 PDE# inhibitors 58 solithromycin 58 HDAC inhibitor 58 antitumor activity 58 Squalamine 58 Cotara R 58 RiVax ™ 58 Oncaspar 58 signal transduction inhibitor 58 HuMax CD# 58 Mipomersen 58 IMiDs R 58 BrachySil 58 AMPK activators 58 Cerashield 58 KSP inhibitor 58 oncology therapeutics 58 darinaparsin ZIO 58 Valortim R 58 hematological indications 58 CDK inhibitors 58 nanoviricide drug 58 MORAb 58 UPLYSO 58 HepeX B TM 58 XL# inhibits 58 ADP receptor antagonist 58 Hedgehog Pathway Inhibitor 58 Locked Nucleic Acid 58 ARIKACE ™ 58 Omacetaxine 58 PANVAC VF 58 ImmunoVEX HSV2 58 Cloretazine R VNP#M 58 EndoTAGTM 1 58 Cx# [002] 58 ZFN modified 58 Immunotherapeutic 58 Polymer Microspheres 58 Etubics 58 NADiA ProsVue 58 developing Zerenex TM 58 anti EGFR antibody 58 HCV nucleotide polymerase inhibitor 58 anticoagulant reversing agent 58 oral ridaforolimus 58 prodrug 58 CBLB# 58 Insegia 58 INT# [002] 58 delipidation 58 Cintredekin Besudotox 58 autologous cellular immunotherapy 58 CCR9 58 dermatology biopharmaceutical company 58 GVAX R 58 CRLX# 58 anti CD3 58 ADVEXIN 58 product candidate Lpathomab 58 RG# [001] 58 SparVax TM 58 fosbretabulin 58 Diamyd R 58 AACR NCI EORTC 58 Micromet proprietary BiTE 58 ocular formulation 58 recombinant subunit vaccine 58 peptidomimetic 58 delivers fluocinolone acetonide FA 58 IMPDH inhibitor 58 Elesclomol 58 FOLOTYN 58 HuMax TAC 58 HCV NS3 protease 58 OxBC 58 agonistic human 58 cabozantinib 58 DACH platinum 58 novel VDA molecule 58 OMNARIS HFA 58 drug GAP #B# 58 aflibercept 58 investigational HCV polymerase 58 tranilast 58 AEZS 58 Valortim TM 58 nanoviricides 58 cathepsin K inhibitor 58 SNT MC# 58 trastuzumab Herceptin R 58 orthotopic model 58 Nanobody R 58 HuCAL antibodies 58 Xanafide 58 Zenvia ™ 58 MEK Inhibitor 58 FOLOTYN ® 58 CB2 selective receptor agonist 58 metastatic CRC 58 potent antiproliferative 58 RNA interference RNAi therapeutics 58 mda 7 58 tezampanel 58 DCVax ® Brain 58 MKC# PP 58 TRX1 58 PEGylated interferon 58 CYT# 58 Poly ICR 58 assessing T DM1 58 SCIB1 58 Loramyc R 58 highly immunogenic 58 monoclonal antibodies 58 vosaroxin 58 antibody fragment 58 EGFr 58 OGeS 58 Phase Ib II 58 HCV protease inhibitors 58 MOR# 58 Prednisporin TM 58 Preclinical studies 58 HER2 positive metastatic breast 58 small molecule 58 sapacitabine 58 CALAA 58 SB# ONX 58 Fc fusion protein 58 castrate resistant prostate cancer 58 PF # [001] 58 injectable formulation 58 NS4A 58 intranasal formulation 58 MET inhibitor 58 Aganocide 58 oncolytic vaccine 58 ISIS # 58 Abiraterone acetate 58 PolyActive ® 58 Neo Urinary Conduit 58 solid tumors 58 Campath ® 58 thalidomide Thalomid 58 Prodarsan ® 58 molecular chaperone regulation 58 NexACT 58 Belinostat 58 LEUKINE 58 vinca alkaloid 58 oncolytic virus therapies 58 Xyfid TM 58 SERMs 58 zanolimumab 58 Neo Kidney Augment ™ 58 FavId 58 ON #.Na 58 SGLT2 58 apoptosis proteins 58 5 HT4 receptor 58 mifamurtide 58 KRN# 58 therapeutic antibodies 58 palifosfamide Zymafos TM 58 Leukine ® 58 VEGF Trap 58 CA9 SCAN 58 CD4 monoclonal antibody 58 Listeria vaccine 58 anti leukemic 58 Sangamo ZFP technology 58 eTag assays 58 Uvidem 58 biomarker identification 58 platinum chemotherapeutic 58 Besivance 58 DiLA2 58 Opexa 58 REOLYSIN ® 58 acetonide FA 58 Pertuzumab 58 docetaxel Taxotere R 58 isatoribine 58 Xcytrin R 58 StaphVAX R 58 IgG1 antibody 58 Targeted Chemotherapy 58 Bendamustine 58 OTCBB HXBM developer 58 ALV# 58 HCV antiviral 58 GammaCan 58 kidney urologic 58 ANG# 58 LungExpress Dx TM 58 BioNumerik 58 tkRNAi technology 58 apaziquone 57 ponatinib 57 TransVax tm 57 luteinizing hormone releasing 57 AKT inhibitor 57 triphendiol 57 allosteric modulation 57 Anticalins 57 XL# XL# XL# 57 HepDirect 57 candidate AQ4N 57 tumorigenicity 57 Nexavar ® 57 ONCONASE 57 protein tyrosine phosphatase 1B 57 Cardio Vascu Grow 57 bispecific antibodies 57 IIa trial 57 sulodexide 57 immatics 57 MET amplification 57 AAG geldanamycin analog 57 trastuzumab emtansine T DM1 57 modified glutathione analog 57 Epratuzumab 57 Junovan TM 57 Anticalins R 57 5 HT6 antagonist 57 telomerase inhibitor 57 neratinib 57 Excellarate 57 epithelial tumors 57 CDK inhibitor 57 BRIM2 57 antisense inhibitor 57 Lpath 57 Myocet 57 SUCCEED trial 57 SMaRT ™ 57 alkylating agent 57 AGS PSCA 57 ANYARA 57 INGN 57 anti CTLA 57 StemEx R 57 Sphingomab TM 57 proprietary BiTE ® 57 novel peptides 57 multiple myeloma MM 57 DDP# 57 human monoclonal antibody 57 superficial bladder cancer 57 lumiliximab 57 adenoviral vectors 57 tumor xenograft models 57 HCV NS5B polymerase 57 seliciclib CYC# 57 AN# novel 57 Cyclosert 57 Curaxin CBLC# 57 IGF 1R inhibitor 57 radezolid 57 AKIP ™ 57 TRIOLEX 57 cancer immunotherapy 57 TGR5 57 rALLy trial 57 oritavancin 57 Fleximer R 57 Xencor XmAb 57 investigational immunotherapy 57 celgosivir 57 DB# [003] 57 PARP inhibitor 57 Bortezomib 57 Zybrestat 57 Vegenics 57 ASG 5ME 57 HCV polymerase 57 OncoVex 57 thrombin inhibitor 57 PSN# [001] 57 potent anticancer 57 prostone 57 generation Hsp# inhibitor 57 daptomycin 57 dacetuzumab SGN 57 TLK# 57 Dalbavancin 57 Chrysalin 57 GLPG# 57 Fx #A 57 Cotara ® 57 Intravenous CP 57 Trofex ™ 57 antiangiogenesis 57 Zensana TM 57 Bioral ® 57 MKC# MT 57 Phase #b/#a trial 57 BioWa 57 Aurora Kinase 57 Glufosfamide 57 ZFP Therapeutics 57 QLT# 57 fatty acid amide hydrolase 57 Spiro Rombotis President 57 tremelimumab 57 HE# [002] 57 sunitinib Sutent ® 57 NEUVENGE 57 prodrugs 57 HDL Selective Delipidation 57 CIMZIA ™ 57 rNAPc2 57 vivo efficacy 57 tafamidis 57 gastro intestinal inflammation 57 Nicole Onetto MD 57 preclinical models 57 TBC# 57 Marqibo 57 nucleoside analog 57 CINTREDEKIN BESUDOTOX 57 Angiolix 57 Viprovex TM